Statute Details
- Title: Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021
- Act Code: HPA2007-S104-2021
- Type: Subsidiary Legislation (sl)
- Authorising Act: Health Products Act (Cap. 122D)
- Enacting authority: Health Sciences Authority (HSA), with approval of the Minister for Health
- Commencement: Not specified in the provided extract (commencement is addressed in section 1)
- Status: Current version as at 27 Mar 2026
- Key Parts (high level): Part 1 Preliminary; Part 2 Manufacture; Part 3 Import; Part 4 Supply; Part 5 Supply requirements; Part 6 Presentation; Part 7 Registration; Part 8 Duties/obligations; Part 9 Certification; Part 10 General provisions
- Key definitions anchor: Section 2 (definitions)
- Clinical research exclusion: Section 3 (clinical research CTGT products excluded)
- Most operational provisions (from extract): Licensing/registration, supply without registration, traceability, adverse event reporting, recall notification, and certification for export
- Noted amendments in timeline (from extract): SL 104/2021; S 1076/2021; S 451/2022; S 437/2023; S 801/2023
What Is This Legislation About?
The Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (“CTGT Regulations”) form the core Singapore regulatory framework for cell, tissue and gene therapy products—often referred to as “CTGT products”. These are advanced medicinal products that may involve living cells, engineered tissues, or genetic material intended to treat, prevent, or diagnose disease. Because of their complexity and potential risks, the Regulations impose licensing, registration, quality, traceability, and safety obligations across the lifecycle of CTGT products.
In plain language, the Regulations decide who may manufacture, import, and supply CTGT products in Singapore, when licences or registration are required, and what conditions must be met for quality and patient safety. They also regulate how CTGT products are presented to the public (including trade descriptions and required information), and they create duties to maintain records, report defects and adverse effects, and notify the Authority about recalls.
Importantly, the Regulations carve out exceptions for certain categories of CTGT products (for example, minimally manipulated products, research or non-clinical purposes, and specific supply scenarios). They also address “unregistered” supply in limited circumstances, including consent and information duties. For practitioners, the key takeaway is that compliance is not limited to registration alone; it extends to ongoing obligations for licensed/known manufacturers, importers, wholesalers, and registrants.
What Are the Key Provisions?
1) Preliminary scope and exclusions. Part 1 sets the foundation. Section 2 provides definitions that control how terms such as “CTGT products”, “minimally manipulated”, “Class 1/2”, and other regulatory concepts are interpreted. Section 3 excludes “clinical research CTGT products” from the Regulations. This is significant because clinical research is typically governed by separate regulatory pathways (e.g., clinical trial authorisation frameworks). Practitioners should therefore confirm whether a product is being supplied for clinical research versus clinical use, as the compliance route may differ.
2) Manufacture: licensing and exceptions. Part 2 governs CTGT product manufacture. Division 1 provides exceptions to the need for a manufacturer’s licence. For example, section 4 addresses manufacturing “minimally manipulated CTGT products”, and section 5 addresses manufacturing other CTGT products for research or non-clinical purposes. Division 2 then sets out the requirements for a manufacturer’s licence (section 6). While the extract does not reproduce the full text of section 6, the structure indicates that the licence regime is the default for manufacturing CTGT products that fall outside the exceptions.
For legal compliance, the practical question is whether the activity is “manufacture” under the Regulations and whether the product is “minimally manipulated” or intended for research/non-clinical purposes. If not, a manufacturer’s licence is likely required. Even where an exception applies, other duties in Part 8 may still be relevant depending on the status of the supplier (e.g., recordkeeping, traceability, and reporting obligations).
3) Import: licensing and exceptions. Part 3 mirrors the manufacture structure. Division 1 contains exceptions to the need for an importer’s licence, including importing minimally manipulated CTGT products (section 7) and importing to manufacture CTGT products (section 8). Division 2 sets requirements for an importer’s licence (section 9). The licensing logic is similar: importers must be authorised unless the import falls within an exception. Practitioners should also consider whether the importer is importing for subsequent local manufacture, for supply, or for export-only purposes—because later provisions in Part 4 also create export-related exceptions for wholesale supply.
4) Supply: licensing, registration, and “unregistered” pathways. Part 4 is the most commercially sensitive section set because it regulates supply (including wholesale and retail-adjacent activities). Division 1 provides exceptions to the need for a wholesaler’s licence. These include supplying minimally manipulated CTGT products by wholesale (section 10), wholesale supply of other CTGT products for research or non-clinical purposes (section 11), and several specific scenarios: transfers by healthcare service licensees (section 12), wholesale supply of CTGT products imported solely for export (section 13), and wholesale supply of self-manufactured CTGT products (section 14).
Division 2 addresses supply of CTGT products without registration. This is where the Regulations become particularly important for patient-facing and operational compliance. Section 15 sets out “prescribed exceptions” (the details are not in the extract, but the existence of a prescribed list suggests tightly controlled categories). Section 16 permits supply of “Class 1” CTGT products (again, the full conditions are not shown in the extract). Section 17 imposes a duty to obtain consent and provide information for supply of unregistered Class 2 CTGT products in certain circumstances. This provision is a clear legal safeguard: even where registration is not required (or not yet obtained), the Regulations require informed consent and disclosure of specified information.
Section 18 allows supply of CTGT products manufactured under an agreement with a licensed or known manufacturer. This is a common compliance pattern in regulated supply chains: a party may not be the manufacturer but can supply products manufactured under a contractual arrangement with an authorised or “known” manufacturer. Practitioners should therefore pay attention to how “known manufacturer” is defined and what evidence must be retained to demonstrate the contractual and regulatory relationship.
5) Supply requirements and recordkeeping. Part 5 sets operational supply requirements. Section 20 governs wholesale supply of Class 2 CTGT products. Section 21 addresses supply by retail sale, and section 22 addresses supply by administration of CTGT products (which may involve healthcare providers). Section 23 requires records of supply of prescribed CTGT products. These provisions collectively ensure that the Authority can audit supply chains and trace product movement and use.
6) Presentation: trade descriptions and information duties. Part 6 regulates how CTGT products are marketed and presented. Section 24 addresses trade descriptions. Section 25 requires information to be provided with CTGT products. Section 26 addresses supply by dispensing CTGT products. Section 27 deals with re-labelling of unregistered Class 2 CTGT products without a manufacturer’s licence, and section 28 provides for corrective measures where there are contraventions relating to trade descriptions or failure to provide prescribed information. For practitioners, this part is often where regulatory risk intersects with consumer protection and professional conduct issues.
7) Registration of CTGT products. Part 7 is the formal regulatory pathway for bringing CTGT products into Singapore under a registration regime. Section 29 sets out requirements for registration. Section 29A introduces a prescribed time for cancellation of registration for non-payment of a retention fee—this is a practical compliance point: even a previously registered product can be removed if fees are not paid within the specified timeframe. Section 30 requires disclosure of information on applications for registration, indicating transparency obligations in the application process.
For counsel advising registrants, the key is to treat registration as an ongoing status, not a one-off approval. Fee retention, data validity, and post-registration obligations in Part 8 (including risk management and benefit-risk reporting) are likely to be critical.
8) Duties and obligations: traceability, adverse effects, recall, and risk management. Part 8 is structured into three divisions: general duties (Division 1), duties specific to licensed/known manufacturers/importers/wholesalers (Division 2), and duties specific to registrants (Division 3).
Division 1 includes routine inspections (section 31), recordkeeping for manufacture (section 32), records of receipt and supply (section 33), a system of traceability (section 34), records of defects and adverse effects (section 35), reporting defects and adverse effects (section 36), and notifying the Authority concerning recall (section 37). Section 38 requires a supplier of an unregistered Class 1 CTGT product to provide information. These provisions create a comprehensive safety net: the Regulations anticipate that problems may arise and require rapid reporting and traceability to enable corrective action.
Division 2 includes duties for licensed or known manufacturers (section 39), importers (section 40), wholesalers (section 41), and information duties for known manufacturers/importers/wholesalers (section 42). It also introduces a “responsible person” concept (section 43), offences for contravention of duties (section 44), and administrative duties relating to changes affecting licences and notices (sections 45–47). The presence of an “offence” provision underscores that compliance failures can trigger criminal or regulatory enforcement consequences.
Division 3 imposes duties on registrants: changes concerning registered CTGT products (section 48), information on validity of data submitted or considered by the Authority (section 49), submission of benefit-risk evaluation reports (section 50), and a duty to carry out a risk management plan (section 51). These are hallmark pharmacovigilance and lifecycle management obligations, aligning CTGT regulation with broader medicines safety principles.
9) Certification for export. Part 9 provides certification mechanisms. Section 52 addresses certification of CTGT products intended for export. Sections 53 and 54 cover certificates of manufacturing standard and distribution standard, respectively. Section 55 allows other certificates or documents. This matters for companies operating cross-border supply chains: Singapore may require formal evidence that exported CTGT products meet specified standards.
10) General provisions. Part 10 includes product quality surveillances (section 56), non-compliant CTGT products (section 57), confidential information (section 58), and saving/transitional provisions (section 60). These provisions support enforcement and continuity during regulatory transitions.
How Is This Legislation Structured?
The Regulations are organised into ten Parts, moving logically from scope and definitions (Part 1) to the regulated lifecycle activities: manufacture (Part 2), import (Part 3), and supply (Part 4 and Part 5). They then address how products are presented (Part 6), formal market authorisation via registration (Part 7), ongoing compliance duties (Part 8), and export certification (Part 9). Part 10 contains general enforcement and administrative provisions, including quality surveillance, handling of non-compliant products, confidentiality, and transitional rules. The Schedule is indicated as “repealed” in the extract, suggesting prior transitional or listing content has been removed.
Who Does This Legislation Apply To?
The Regulations apply to persons involved in the manufacture, import, wholesale supply, retail sale, and administration of CTGT products in Singapore, as well as to registrants of CTGT products. The obligations are not uniform: different duties attach depending on whether a party is a licensed manufacturer/importer/wholesaler, a “known” manufacturer/importer/wholesaler, a registrant, or a supplier operating under an exception or unregistered supply pathway.
Healthcare service licensees may be relevant under section 12 (transfer of Class 2 CTGT products) and under Part 5 supply by administration (section 22). Practitioners should therefore assess not only corporate roles (manufacturer/importer/wholesaler) but also operational roles in clinical settings, where consent, information provision, and administration duties may arise.
Why Is This Legislation Important?
CTGT products present distinctive regulatory challenges: they are often complex biological products, may have variable manufacturing processes, and can carry significant patient safety risks. The CTGT Regulations operationalise Singapore’s approach to managing those risks through licensing, registration, and lifecycle obligations. For lawyers, the Regulations provide a clear compliance architecture that can be mapped onto corporate structures and supply chain contracts.
From an enforcement perspective, the Regulations are designed to enable traceability and rapid response. The combination of traceability systems (section 34), defect/adverse effect recordkeeping and reporting (sections 35–36), and recall notification (section 37) creates a legally enforceable framework for pharmacovigilance and quality control. The inclusion of offences for contravention of duties (section 44) further indicates that compliance failures are not merely administrative.
Practically, the Regulations also affect commercial decisions: whether to seek registration, how to structure manufacturing agreements with licensed or known manufacturers (section 18), how to handle unregistered Class 2 supply (section 17), and how to manage ongoing obligations such as benefit-risk reporting and risk management plans (sections 50–51). Counsel advising sponsors, manufacturers, importers, wholesalers, and healthcare providers should treat these provisions as contract and compliance design requirements, not only regulatory checklists.
Related Legislation
- Health Products Act (Cap. 122D) (authorising Act)
- Healthcare Services Act 2020
- Medical Registration Act 1997
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.